[1]张泽天,吴 娜,杨婕琳,等.NLR、血清EFNA1与胃癌患者临床病理特征及预后关系研究[J].陕西医学杂志,2026,(5):685-690，696.[doi:DOI:10.3969/j.issn.1000-7377.2026.05.020]
　ZHANG Zetian,WU Na,YANG Jielin,et al.Relationship between NLR,serum EFNA1 and clinicopathological features and prognosis in patients with gastric cancer[J].,2026,(5):685-690，696.[doi:DOI:10.3969/j.issn.1000-7377.2026.05.020]
点击复制

NLR、血清EFNA1与胃癌患者临床病理特征及预后关系研究

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2026年5期
页码:
685-690，696
栏目:
临床病理
出版日期:
2026-05-05

文章信息/Info

Title:
Relationship between NLR,serum EFNA1 and clinicopathological features and prognosis in patients with gastric cancer
作者:
张泽天; 吴 娜; 杨婕琳; 张 翔; 梁 娜
（河北北方学院附属第一医院消化内科，河北 张家口 075000）
Author(s):
ZHANG Zetian; WU Na; YANG Jielin; ZHANG Xiang; LIANG Na
(Department of Gastroenterology,the First Affiliated Hospital of Hebei North University,Zhangjiakou 075000,China)
关键词:
胃癌; 中性粒细胞与淋巴细胞比值; 肝配蛋白A1; 临床病理特征; 预后; 预测价值
Keywords:
Gastric cancer; Neutrophil-to-lymphocyte ratio; Ephrin-A1; Clinicopathological features; Prognosis; Predictive value
分类号:
R735.2
DOI:
DOI:10.3969/j.issn.1000-7377.2026.05.020
文献标志码:
A
摘要:
目的：探讨中性粒细胞与淋巴细胞比值（NLR）、血清肝配蛋白A1（EFNA1）与胃癌患者临床病理特征及预后的关系。方法：选取接受胃癌根治术治疗的128例胃癌患者及128例无胃肠道疾病的体检健康者为研究对象，分别纳入胃癌组和胃肠道健康组。其中，胃癌组87例患者根治术后3年内未出现肿瘤进展，纳入术后未进展组；41例患者根治术后3年内出现肿瘤进展，纳入术后进展组。采用全自动血细胞分析仪和酶联免疫吸附试验检测胃癌组和胃肠道健康组全血NLR及血清EFNA1水平；采用多因素Logistic回归分析胃癌患者根治术后3年内肿瘤进展的影响因素；采用受试者工作特征（ROC）曲线评估NLR、血清EFNA1对胃癌患者根治术后3年内发生肿瘤进展的预测价值。结果：胃癌组患者NLR、血清EFNA1水平较胃肠道健康组升高（均P＜0.05）。胃癌组NLR、血清EFNA1水平与TNM分期和肿瘤浸润深度有关（均P＜0.05）。术后进展组TNM分期Ⅲ期、肿瘤浸润深度突破浆膜患者比例及NLR、血清EFNA1水平高于术后未进展组（均P＜0.05）。TNM分期、肿瘤浸润深度、NLR、血清EFNA1为胃癌患者根治术后肿瘤进展的影响因素（均P＜0.05）。NLR、血清EFNA1联合预测胃癌患者根治术后3年内发生肿瘤进展的曲线下面积（AUC）为0.941，高于NLR、血清EFNA1单独预测的AUC（均P＜0.05）。结论：胃癌患者NLR、血清EFNA1水平升高，与肿瘤TNM分期及浸润深度有关，二者联合预测胃癌患者根治术后3年内发生肿瘤进展的价值较高。
Abstract:
Objective:To investigate the relationship between neutrophil-to-lymphocyte ratio (NLR),serum ephrin-A1 (EFNA1),and clinicopathological features and prognosis in patients with gastric cancer.Methods：A total of 128 gastric cancer patients undergoing radical gastrectomy and 128 healthy individuals without gastrointestinal diseases were enrolled as the gastric cancer group and the gastrointestinal healthy group,respectively.Among the gastric cancer group,87 patients without tumor progression within 3 years after radical surgery were assigned to the non-progression group,and 41 patients with tumor progression within 3 years were assigned to the progression group.The whole blood NLR and serum EFNA1 levels were measured by automatic blood cell analyzer and enzyme-linked immunosorbent assay.Multivariate logistic regression analysis was used to analyze the influencing factors of tumor progression within 3 years after radical gastrectomy.ROC curve was applied to evaluate the predictive value of NLR and serum EFNA1 for tumor progression within 3 years after radical surgery.Results:NLR and serum EFNA1 levels in the gastric cancer group were significantly higher than those in the gastrointestinal healthy group (all P<0.05).NLR and serum EFNA1 levels in gastric cancer patients were associated with TNM stage and tumor invasion depth (all P<0.05).The proportion of patients with TNM stage Ⅲ and tumor invasion beyond the serosa,as well as NLR and serum EFNA1 levels in the progression group were significantly higher than those in the non-progression group (all P<0.05).TNM stage,tumor invasion depth,NLR,and serum EFNA1 were independent influencing factors for tumor progression after radical gastrectomy (all P<0.05).The AUC of NLR combined with serum EFNA1 in predicting tumor progression within 3 years was 0.941,which was higher than that of NLR or serum EFNA1 alone (all P<0.05).Conclusion:Elevated NLR and serum EFNA1 levels are found in gastric cancer patients and are related to TNM stage and tumor invasion depth.The combination of NLR and serum EFNA1 shows high predictive value for tumor progression within 3 years after radical gastrectomy.

参考文献/References:

[1]SHAH D,BENTREM D.Environmental and genetic risk factors for gastric cancer[J].J Surg Oncol,2022,125(7):1096-1103.
[2]MOTT T,GRAY C.Gastric cancer:Rapid evidence review[J].Am Fam Physician,2025,111(2):140-145.
[3]PRADHAN S P,GADNAYAK A,PRADHAN S K,et al.Epidemiology and prevention of gastric cancer:A comprehensive review[J].Semin Oncol,2025,52(3):152341.
[4]WANG Z,WU Q.Advancements in non-invasive diagnosis of gastric cancer[J].World J Gastroenterol,2025,31(6):101886.
[5]黄丹丹,陈志祥,吴文龙,等.外周血红细胞分布宽度、平均血小板容积、中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值和淋巴细胞与单核细胞比值对肺癌的诊断价值研究[J].陕西医学杂志,2024,53(8):1047-1050.
[6]BUONACERA A,STANCANELLI B,COLACI M,et al.Neutrophil to lymphocyte ratio:An emerging marker of the relationships between the immune system and diseases[J].Int J Mol Sci,2022,23(7):3636-3645.
[7]TAN S,ZHENG Q,ZHANG W,et al.Prognostic value of inflammatory markers NLR,PLR,and LMR in gastric cancer patients treated with immune checkpoint inhibitors:A meta-analysis and systematic review[J].Front Immunol,2024,15:1408700.
[8]CUI Y,CHANG Y,MA X,et al.Ephrin A1 stimulates CCL2 secretion to facilitate premetastatic niche formation and promote gastric cancer liver metastasis[J].Cancer Res,2025,85(2):263-276.
[9]CHU L Y,HUANG B L,HUANG X C,et al.EFNA1 in gastrointestinal cancer:Expression,regulation and clinical significance[J].World J Gastrointest Oncol,2022,14(5):973-988.
[10]张贺龙,刘文超.临床肿瘤学[M].西安:第四军医大学出版社,2015:260-272,319.
[11]MATSUOKA T,YASHIRO M.Bioinformatics analysis and validation of potential markers associated with prediction and prognosis of gastric cancer[J].Int J Mol Sci,2024,25(11):5880-5902.
[12]YANG W J,ZHAO H P,YU Y,et al.Updates on global epidemiology,risk and prognostic factors of gastric cancer[J].World J Gastroenterol,2023,29(16):2452-2468.
[13]MAIORINO L,DALER-PLENKER J,SUN L,et al.Innate immunity and cancer pathophysiology[J].Annu Rev Pathol,2022,17(2):425-457.
[14]MOUKAS S I,KASIMIR-BAUER S,TEWES M,et al.Ratios of monocytes and neutrophils to lymphocytes in the blood predict benefit of CDK4/6 inhibitor treatment in metastatic breast cancer[J].Sci Rep,2023,13(1):21262-21278.
[15]代佳,李林,贺林,等.中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值与肺癌早期诊断以及临床病理特征相关性分析[J].陕西医学杂志,2023,52(4):468-471.
[16]WATANABE J,KIMURA T,SAZE Z,et al.The ratio of intratumoral CD15 neutrophils to CD8 lymphocytes predicts recurrence in patients with gastric cancer after curative resection[J].Cancer Rep (Hoboken),2024,7(6):e2099.
[17]ZHANG S,QIU C,YU H,et al.Prognostic value of neutrophil to lymphocyte ratio in gastric cancer patients receiving immune checkpoint inhibitors:A systematic review and meta-analysis[J].Front Oncol,2023,13:1070019.
[18]ZHANG X,WANG X,LI W,et al.Predictive value of neutrophil-to-lymphocyte ratio for distant metastasis in gastric cancer patients[J].Sci Rep,2022,12(1):10269-10275.
[19]URAKAWA N,KANAJI S,KATO T,et al.Neutrophil-lymphocyte ratio and histological response correlate with prognosis of gastric cancer undergoing neoadjuvant chemotherapy[J].In Vivo,2023,37(1):378-384.
[20]NGUYEN M L T,PHAM C,LE Q V,et al.The diagnostic and prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio on gastric cancer patients[J].Medicine (Baltimore),2023,102(31):e34357.
[21]HAO Y P,WANG W Y,QIAO Q,et al.EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma[J].Medicine (Baltimore),2021,100(22):e26188.
[22]LI S,SUN M,CUI Y,et al.Ephrin A1 functions as a ligand of EGFR to promote EMT and metastasis in gastric cancer[J].EMBO J,2025,44(5):1464-1487.
[23]CHU L Y,WU F C,GUO H P,et al.Combined detection of serum EFNA1 and MMP13 as diagnostic biomarker for gastric cancer[J].Sci Rep,2024,14(1):15957.
[24]HAO Y,LI G.Role of EFNA1 in tumorigenesis and prospects for cancer therapy[J].Biomed Pharmacother,2020,130(1):110567-110574.
[25]XIE R,YUAN M,JIANG Y.The pan-cancer crosstalk between the EFNA family and tumor microenvironment for prognosis and immunotherapy of gastric cancer[J].Front Cell Dev Biol,2022,10(3):790947-790962.
[26]DONG X,CHEN X,XUE M,et al.EFNA1 promotes the tumorigenesis and metastasis of cervical cancer by phosphorylation pathway and epithelial-mesenchymal transition[J].Acta Histochem,2025,127(2):152236.

相似文献/References:

[1]侯洁心 ,郭萍△.免疫组化标志物Her2和肿瘤标志物在胃癌诊断中的价值分析*[J].陕西医学杂志,2019,(1):121.
　HOU Jiexin,GUO Ping..The value of immunohistochemical marker Her2 andtumor markers in the diagnosis of gastric cancer[J].,2019,(5):121.
[2]唐亚荣.循环热灌注化疗联合替吉奥及热疗治疗老年胃癌癌性腹水临床研究*[J].陕西医学杂志,2019,(4):435.
　TANG Yarong..Clinical effect analysis of combined therapy with tiago and hyperthermia in the treatment of malignant ascites in elderly patients with gastric cancer[J].,2019,(5):435.
[3]刘国庆,闫 龙△,高 任.1.5T磁共振扩散加权成像在胃癌淋巴结转移诊断中的应用价值*[J].陕西医学杂志,2019,(4):456.
　LIU Guoqing,YAN Long,GAO Ren..1.5T magnetic resonance diffusion weighted imaging in the diagnosis of lymph node metastasis of gastric cancer[J].,2019,(5):456.
[4]胡乃军,王海龙.胃腺癌组织中MMP11、MMP12和VEGFD的表达及临床意义[J].陕西医学杂志,2019,(5):554.
[5]米志宽,赵菊梅.抑癌基因甲基化与胃癌关系研究进展*[J].陕西医学杂志,2019,(5):679.
　MI Zhikuan,ZHAO Jumei..Research progress of relationships between tumor suppressor gene methylation and gastric cancer[J].,2019,(5):679.
[6]石颖鹏,王敏娟,李程亮.肠化生相关分子与胃癌的发生和进展研究概况[J].陕西医学杂志,2019,(7):958.
　SHI Yingpeng,WANG Minjuan,LI Chengliang,et al.Intestinal metaplasia-related molecules and the occurrence and progress of gastric cancer[J].,2019,(5):958.
[7]郭小艳,于桂萍.抗幽门螺杆菌疗法联合新辅助化疗对胃癌术后疗效及患者血清VEGF、bFGF的影响[J].陕西医学杂志,2019,(8):1010.
　GUO Xiaoyan,YU Guiping..Effect of anti-Helicobacter pylori therapy combined with neoadjuvant chemotherapy on serum VEGF and bFGF in postoperative patients with gastric cancer[J].,2019,(5):1010.
[8]柯东平,毛俊倩,郭甲民,等.SCNN1B与胃癌细胞上皮间质转化相关性实验研究*[J].陕西医学杂志,2019,(9):1115.
　KE Dongping,MAO Junqian,GUO Jiamin,et al.Research on the correlation between SCNN1B and〖JZ〗 epithelialmesenchymal transformation in gastric cancer cells[J].,2019,(5):1115.
[9]王小林,马任远,张 哲.腹腔镜手术治疗老年进展期胃癌50例临床疗效分析[J].陕西医学杂志,2019,(10):1360.
[10]张秀娟,高喜松△.中性粒细胞淋巴细胞比值与急性特发性周围性面神经麻痹严重程度和恢复时间相关性研究[J].陕西医学杂志,2019,(11):1529.

备注/Memo

备注/Memo:
河北省医学科学研究课题（20200500）；河北省张家口市科技计划自筹经费项目（2221175D）
更新日期/Last Update: 2026-05-05